Canadian-made Ebola vaccine to start clinical trials in healthy humans

Canadian-made Ebola vaccine to start clinical trials in healthy humans

An experimental Canadian-made Ebola vaccine will begin a clinical trials Monday in what officials are calling a promising development in the fight against the deadly disease.

The vaccine will be tested on healthy individuals to see how well it works, whether there are side effects and what the proper dosage is

A small U.S. company called NewLink Genetics holds the license for the vaccine and will be arranging the trials, to be conducted in a lab in Silver Spring, Md.
Source: Global News



t is important to note in the Archives that healthy human trial have already been conducted back in 2003, and prior in 1998.

What is missing are the tests results and the overall studies conclusions. Remember the Archive is for public notice and release for press the results however are not available.

What happened to these people? What were the conclusions of these studies back in 1998 – 2003?  Please read the provided White Papers below.


100% proof the Media is lying to us:

They state in this video “The first ever healthy Human test subject” also notice the panic and urgency to test the vaccines NOW!

Who or what is the Wellcome Trust: The Wellcome Trust Sanger Institute: < click the link to their website.

The Trust has been described by the Financial Times as the United Kingdom’s largest provider of non-governmental funding for scientific research and one of the largest providers in the world. In the field of medical research, it is the world’s second largest private funder after Bill & Melinda Gates Foundation


The Trust was established to administer the fortune of the American-born pharmaceutical magnate Sir Henry Wellcome. Its income was derived from what was originally called Burroughs Wellcome, later renamed in the UK as the Wellcome Foundation Ltd. In 1986, the trust sold 25% of Wellcome plc stock to the public. Overseen by incoming Director of Finance Ian Macgregor, this marked the beginning of a period of financial growth that saw the Trust’s value increase by almost £14bn in 14 years, as their interests moved beyond the bounds of the pharmaceutical industry. In 1995, the trust divested itself of any interest in pharmaceuticals by selling all remaining stock to Glaxo plc, the company’s historic British rival, creating GlaxoWellcome plc. In 2000, the Wellcome name disappeared from the drug business altogether when GlaxoWellcome merged with SmithKline Beecham, to form GlaxoSmithKline plc.

source: Wellcome Trust


Why would this institution also connect itself to Sanger Institute:

Read More: In The Mind Of The Psychopath: Margaret Sanger

Margaret Sanger classified as a leading intellectual, was a key part in putting forward an ideal of Planned Parenthood instead of looking at the overall solutions of properly feeding people. Her solution was to discourage any births on various “Types” of populations. Under the guise of helping Mothers of Unwanted Births her focus was to encourage women to reduce births as a non sin of taking life. Her perceptions changed the world in regard to population control. While under the guise of safe abortion and safe reduced birth rates, she soon was in large part a major contributor to not only birth control but a outright Eugenics.

The main push today is to express they have to test for todays standards on Healthy subjects. Ebola does not change it has been around for a very long time. The obvious conclusion in my opinion is:

Trials were first arranged to see if they could vaccine the population through food (or possibly contaminate the population through food) then create a vaccine to counter the results of those infected. Problem (create a manipulated cotangent/Reaction (create panic so the populace will receive the vaccine)/Solution (provide the vaccine they ask for with an extra bonus – sterilization). Please read the following archived research projects from the source of the tests. Keep in mind the Sanger / Gates connections.

Vaccines tested in Genetically Modified Foods: The Delivery Stage: Contaminate the Healthy

Monday, April 27, 1998

Media Contact:
Laurie K. Doepel
(301) 402-1663

First Human Trial Shows that an Edible Vaccine is Feasible

Opening a new era in vaccine delivery, researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) have shown for the first time that an edible vaccine can safely trigger significant immune responses in people. The report, by collaborators from the University of Maryland in Baltimore, the Boyce Thompson Institute for Plant Research in Ithaca, N.Y., and Tulane University in New Orleans, appears in the May issue of Nature Medicine.

“Edible vaccines offer exciting possibilities for significantly reducing the burden of diseases like hepatitis and diarrhea, particularly in the developing world where storing and administering vaccines are often major problems,” says Anthony S. Fauci, M.D., director of NIAID.

The Phase 1 proof-of-concept trial began last fall at the University of Maryland School of Medicine’s Center for Vaccine Development under the direction of Carol O. Tacket, M.D., professor of medicine. The goal of the study was to demonstrate that an edible vaccine could stimulate an immune response in humans. Volunteers ate bite-sized pieces of raw potato that had been genetically engineered to produce part of the toxin secreted by the Escherichia coli bacterium, which causes diarrhea.

Previously, NIAID-supported in vitro and preclinical studies by John Clements, Ph.D., and colleagues at Tulane University School of Medicine showed that transgenic potatoes containing this segment of the toxin stimulated strong immune responses in animals. The transgenic potatoes were created and grown by Charles Arntzen, Ph.D., and Hugh S. Mason, Ph.D., and their colleagues at the Boyce Thompson Institute for Plant Research, an affiliate of Cornell University.

The trial enrolled 14 healthy adults; 11 were chosen at random to receive the genetically engineered potatoes and three received pieces of ordinary potatoes. The investigators periodically collected blood and stool samples from the volunteers to evaluate the vaccine’s ability to stimulate both systemic and intestinal immune responses. Ten of the 11 volunteers (91 percent) who ingested the transgenic potatoes had fourfold rises in serum antibodies at some point after immunization, and six of the 11 (55 percent) developed fourfold rises in intestinal antibodies. The potatoes were well tolerated and no one experienced serious adverse side effects.

Encouraged by the results of this study, NIAID-supported scientists are exploring the use of this technique for administering other antigens. Edible vaccines for other intestinal pathogens are already in the pipeline–for example, potatoes and bananas that might protect against Norwalk virus, a common cause of diarrhea, and potatoes and tomatoes that might protect against hepatitis B.

Regina Rabinovich, M.D., oversees NIAID’s Vaccine and Treatment Evaluation Program, of which the University of Maryland’s vaccine center is a part. “This first trial is a milestone on the road to creating inexpensive vaccines that might be particularly useful in immunizing people in developing countries, where high cost and logistical issues, such as transportation and the need for certain vaccines to be refrigerated, can thwart effective vaccination programs,” she comments. “The hope is that edible vaccines could be grown in many of the developing countries where they would actually be used.”

Details of the Study

The study nurse at the University of Maryland peeled the potatoes just before they were eaten, because potato skin sometimes contains a compound that imparts a bitter taste and can cause nausea and stomach upset. The potatoes were then cut into small, uniform pieces and weighed into 50-gram and 100-gram doses. Each person received three doses of either 50 grams or 100 grams of potato over a three-week period, at 0, 7 and 21 days. The dosage size varied in order to evaluate any side effects from eating raw potatoes.



Arntzen CJ. Pharmaceutical foodstuffs—oral immunization with transgenic plants. Nature Medicine (vaccine supplement) 1998;4(5):502-03.

Haq TA, Mason HS, Clements JD, and Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995;268:714-16.

Mason HS, Haq TA, Clements JD, and Arntzen CJ. Edible vaccine protects mice against E. coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine, In Press.

Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM and Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Medicine 1998;4(5):607-09.



The Animal Tests and Trials

Wednesday, August 6, 2003

Media Contact:
Jeff Minerd
(301) 402-1663


Fast-Acting Ebola Vaccine Protects Monkeys

A single shot of a fast-acting, experimental Ebola vaccine successfully protects monkeys from the deadly virus after only one month. If this vaccine proves similarly effective in humans, it may one day allow scientists to quickly contain Ebola outbreaks with ring vaccination—the same strategy successfully used in the past against smallpox, according to a study published in this week’s issue of Nature

This finding is the result of collaboration between scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), and scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, MD.

“This research has enormous public health implications not only because it might be used to limit the spread of Ebola virus, which continues to emerge in central Africa, but also because this vaccine strategy may be applied to other highly lethal viruses, such as the Marburg and Lassa fever viruses and the SARS coronavirus, that cause acute disease outbreaks and require a rapid response,” says NIAID Director Anthony S. Fauci, M.D.

Under the directorship of Gary Nabel, M.D., Ph.D., scientists at the VRC have been pursuing the so-called “prime-boost” vaccine strategy against a variety of infectious diseases. Prime-boost is a two-part process: First, an injection of non-infectious genetic material from the disease-causing microbe primes the immune system to respond. Second, several weeks later, an injection of attenuated carrier viruses containing key genes from the microbe substantially boosts the immune response.

The VRC scientists found that the boost alone produces a quicker but weaker immune response as compared with the prime-boost strategy. Knowing that time is critical when fighting Ebola, the scientists decided to test whether the boost’s fast response was strong enough on its own to protect against the disease. To perform this test, they collaborated with colleagues at USAMRIID, who had the necessary facilities and expertise and who had developed good animal models for the experiment.

The VRC scientists immunized eight monkeys with a single boost injection, consisting of attenuated carrier viruses containing genes for important Ebola antigens. The monkeys were then delivered to USAMRIID where they were injected with an Ebola virus strain obtained from a fatally infected person from the former Zaire in 1995. The single vaccine injection completely protected all eight animals against Ebola infection, even those who received high doses of the virus.

“I am proud that our research team at USAMRIID was able to form an effective partnership with our colleagues at NIAID to develop and evaluate this Ebola vaccine,” comments Peter B. Jahrling, Ph.D., senior research scientist at USAMRIID. “After years of developing candidate Ebola vaccines that protected rodents but failed in primates, it is gratifying to have a vaccine that holds great promise for protection of humans. Eventually, this vaccine may reduce the hazard of working with Ebola virus in the laboratory, as well as provide protection to populations at risk of natural exposure.”

Ebola virus spreads easily from person to person, causes illness quickly and kills a significant number of the people it infects. There is no treatment for the disease, so preventing the spread of the virus is key to containing outbreaks. If the results of this animal study hold true for humans, the new vaccine may be just the Ebola-fighting tool that public health officials need during epidemic outbreaks, Dr. Nabel explains.

“Ring vaccination might be used to stop the spread of the Ebola virus during acute outbreaks, just as this strategy was used to contain smallpox in the past,” Dr. Nabel says. With ring vaccination, everyone who has been in contact with a patient, as well as all members of the patient’s household, are vaccinated. The ring strategy, which requires a fast-acting vaccine, not only protects people who may have been exposed to the virus but also creates an added barrier of immunity around them, thereby protecting the entire community.

Even though the boost alone appears to be effective, the prime-boost strategy, which requires four shots over six months, will still be important to pursue as well, Dr. Nabel says. “The prime-boost strategy elicits a stronger immune response,” he explains, “and it may be useful for preventive vaccines intended for hospital workers at high risk of exposure to the virus, for example.”



N Sullivan et al. Accelerated vaccine for Ebola virus hemorrhagic fever in non-human primates. Nature 424(6949):681-84 (2003).




Then the Healthy Human studies: Minus the conclusions or results of the studies.


New York Times Archives 2003:

Test of an Experimental Ebola Vaccine Begins

Published: November 19, 2003

The first test in humans of an experimental vaccine against the deadly Ebola virus began yesterday, government scientists said.

The vaccine, administered by injection, was designed to try to prevent outbreaks of the lethal hemorrhagic fever where it occurs naturally in Africa. It is also a bid to thwart any efforts to use the highly infectious virus as a bioterrorist agent.

As part of a standard three-stage process, the first phase involves testing the vaccine’s safety. Scientists also plan to measure immune responses among volunteers receiving the shots.

No effective treatment exists against the viral infection, which kills up to 90 percent of victims quickly from severe internal bleeding. Ebola was discovered in 1976 in the Republic of Congo, then Zaire. This week, the World Health Organization reported a new outbreak of Ebola in that country, attributing 11 deaths in as many cases to it.

The experimental DNA vaccine is synthesized using modified, inactivated genes from the Ebola virus. Because it does not contain any infectious material from the virus, recipients cannot get the disease, said Dr. Gary Nabel, who directs the institute’s Vaccine Research Center.

Researchers plan to test the vaccine on 27 people, ages 18 to 44. They are expected to receive three injections of either the experimental vaccine or a placebo at the National Institute of Allergy and Infectious Diseases in Bethesda, Md., over two months. They will then be monitored for a year.

The first volunteer, Steve Rucker, a 36-year-old research nurse at the institute, said in a phone interview that he felt fine after the vaccine was injected in his left arm yesterday.

Mr. Rucker, of College Park, Md., said he was participating because he believed that the findings from animal tests were ”extremely promising.”

Dr. Nabel said in a telephone interview that only a handful of individuals, mostly institute employees, had volunteered for the study and that his team needed at least 20 more volunteers. Details are posted at

The vaccine is made by Vical, a biotechnology company in San Diego that has collaborated with Dr. Nabel’s team as they tested the vaccine on animals.

The goal is to use the Vical vaccine and another one to protect against Ebola in a prime-boost strategy. Under those conditions, the Vical vaccine would be given first to prime the immune system. Then a different vaccine, which uses an adenovirus (that causes colds) would bolster the immune system that had been primed by the Vical vaccine. The second vaccine is still being developed for human use; the first tests in volunteers are expected to begin next year, Dr. Nabel said.

Tests of the prime-boost strategy are expected to begin in 2005. But the schedule depends in part on the findings from the current tests.

Of the volunteers in the Vical study, 21 will get injections of the vaccine and 6 a placebo. Neither the volunteers nor the scientists will know which volunteers received which type of injection until the scientists analyze the results.

The government’s program to defend against bioterrorism has helped accelerate development of a vaccine, said Dr. Anthony S. Fauci, the institute’s director. ”An effective Ebola vaccine not only would provide a life-saving advance in countries where the disease occurs naturally, it also would provide a medical tool to discourage the use of Ebola virus as an agent of bioterrorism,” he said.

The human study is based on animal experiments in which Dr. Nabel’s team gave the two vaccines separately to guinea pigs and monkeys. When the researchers exposed the animals to Ebola virus, they found 100 percent protection, Dr. Nabel said.

A single injection of the adenovirus vaccine provided faster protection than expected.

Because it is unethical to deliberately expose humans vaccinated against Ebola to the virus because the disease is so lethal, scientists and government officials might have to apply what they call ”the two-animal rule.” Government officials recently adopted the rule for possible licensing of a vaccine that proves safe in humans and shows adequate protection against a deliberate infection in two species of animals.

Dr. Nabel said he envisioned that health workers might someday vaccinate against Ebola the same way epidemiologists used the smallpox vaccine to eradicate that disease. The strategy involved vaccinating all possible contacts of the initial cases and then their contacts as well.

Scientists might test the vaccine in an outbreak of Ebola under emergency conditions.


Extending the research on this Archived article by going directly to the source:National Institute of Allergy and Infectious Diseases in Bethesda, Md

It is apparent they have done extensive research on these vaccines that change DNA in 2000.

Direct quote for the article:

Just three years ago, VRC Director Gary Nabel, M.D., Ph.D., together with a team of scientists from the VRC and the Centers for Disease Control and Prevention, described an experimental Ebola vaccine that fully protected monkeys from lethal infection by the virus. One component of that vaccine will now be assessed for safety in human volunteers. The trial vaccine, a type called a DNA vaccine.

Question is why are the press and government agencies lying about healthy human trials? They were fast tracked in Human studies back in 2003. Why do it again? Answer: To get the panic high enough everyone will want the cure.

Will you be willing to take the injection without knowing the full side effects. They have yet to release the conclusions to the prior healthy human tests.

We must look again at RedPillRevolutions video on most of this information: This is critical. The videos Description is critical to the answers. Major work was done by RPR to show you the hidden agenda.




Two days ago, Dr. Anthony Fauci, director of the U.S. National Institute for Allergy and Infectious Diseases, told The Canadian Press that it’s “quite conceivable, if not likely” that fast-tracked Ebola vaccines may have to given to entire countries to get the viral outbreak under control (via Modern Healthcare):

“It is conceivable that this epidemic will not turn around even if we pour resources into it. It may just keep going and going and it might require a vaccine.”

“As the epidemic gets more and more formidable and in some cases out of control it is quite conceivable, if not likely, that we may need to deploy the vaccine to the entire country to be able to shut the epidemic down. That is clearly a possibility.” [emphasis added]

The article did not specify which country in particular Dr. Fauci — whose institute just so happens to be currently working on an experimental Ebola vaccine (the first to begin human clinical trials) with Big Pharma giant GlaxoSmithKline — was referring to. Was he talking specifically about Sierra Leone? Liberia? Guinea? Any place where Ebola has taken hold? The entire continent of Africa? Other countries, should it break out there including Spain or America?


There is a Hidden Agenda regarding this outbreak. Sterilization in the form of a vaccine concoction to eliminate Ebola seems to be one part of the secret behind the push. The connections are all there and the lies are apparent. You draw your own conclusions. Let us know what you think, comment below.

Read More: Toxic Green


Thank You for visiting MaxResistance please like our Facebook and subscribe to our Twitter. If you would like to keep up to date on all our articles please hit the *FOLLOW button at the bottom right of this page and keep up with all our current articles. We ask you to show your support and SHARE our articles and information if you enjoy and like the content. Thank You.





Leave a Reply


Get every new post on this blog delivered to your Inbox.

Join other followers: